

3

4

## PCT

## WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (51) International Patent Classification 7: WO 99/58552 (11) International Publication Number: C07K 14/435, A61K 38/17, A61P 35/00 **A3** (43) International Publication Date: 18 November 1999 (18.11.99) (21) International Application Number: PCT/NO99/00143 (81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, (22) International Filing Date: GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, 3 May 1999 (03.05.99) KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, (30) Priority Data: SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, 19982097 8 May 1998 (08.05.98) NΩ ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI (71) Applicant (for all designated States except US): NORSK HYDRO ASA [NO/NO]; N-0240 Oslo (NO). patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). (72) Inventors; and (75) Inventors/Applicants (for US only): GAUDERNACK, Gustav Published [NO/NO]; Anthon Walles vei 17A, N-1300 Sandvika With international search report. (NO). ERIKSEN, Jon, Amund [NO/NO]; Bjørntvedt 37, N-3916 Porsgrunn (NO). MØLLER, Mona Before the expiration of the time limit for amending the claims [NO/NO]; Skrukkerødtoppen 8, N-3925 Porsgrunn (NO). and to be republished in the event of the receipt of amendments. GJERTSEN, Marianne, Klemp [NO/NO]; Terneveien 10, N-1335 Snarøya (NO). SÆTERDAL, Ingvil [NO/NO]; (88) Date of publication of the international search report: Morgedalsveien 43-8, N-0378 Oslo (NO). 2 March 2000 (02.03.00) (74) Agent: LILLEGRAVEN, Rita; Norsk Hydro ASA, N-0240 Oslo (NO).

## (54) Title: PEPTIDES THAT ELLICIT T, CELLULAR IMMUNITY

## (57) Abstract

Peptides from cancer related protein products of frameshift mutated genes which eliciting T cellular immunity for use in cancer vaccines and compositions for anticancer treatment.